PDE 5 inhibition with udenafil improves left ventricular systolic/diastolic functions and exercise capacity in patients with chronic heart failure with reduced ejection fraction; A 12-week, randomized, double-blind, placebo-controlled trial

American Heart Journal

Volumn 169, Issue 6, 2015, Pages 813-822.e3

  Kim, Kyung Hee ^a,b   Kim, Hyung Kwan ^a   Hwang, In Chang ^a   Cho, Hyun Jai ^a   Je, Nari ^a   Kwon, Oh Min ^a   Choi, Su Jeong ^a   Lee, Seung Pyo ^a   Kim, Yong Jin ^a   Sohn, Dae Won ^a  

^a Seoul National University   (South Korea)

^b Sejong General Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; PHOSPHODIESTERASE V; PLACEBO; UDENAFIL; PHOSPHODIESTERASE V INHIBITOR; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ECHOCARDIOGRAPHY; ENZYME INHIBITION; EPISTAXIS; EXERCISE; FEMALE; FUNCTIONAL STATUS; HEADACHE; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT ATRIUM; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FILLING PRESSURE; HEART LEFT VENTRICLE FUNCTION; HOT FLUSH; HUMAN; HYPOTENSION; LEFT VENTRICULAR DIASTOLIC FUNCTION; LEFT VENTRICULAR SYSTOLIC FUNCTION; MALE; MIDDLE AGED; MYALGIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VISUAL DISORDER; AGED; CHRONIC DISEASE; DRUG EFFECTS; ECHOGRAPHY; EXERCISE TEST; EXERCISE TOLERANCE; HEMODYNAMICS; OXYGEN CONSUMPTION; PATHOPHYSIOLOGY; PROSPECTIVE STUDY;

AGED; CHRONIC DISEASE; DOUBLE-BLIND METHOD; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HEART FAILURE; HEMODYNAMICS; HUMANS; MALE; MIDDLE AGED; OXYGEN CONSUMPTION; PHOSPHODIESTERASE 5 INHIBITORS; PROSPECTIVE STUDIES; PYRIMIDINES; SULFONAMIDES; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 84930180997     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2015.03.018     Document Type: Article

References (35)

1. H. Eriksson Heart failure: a growing public health problem J Intern Med 237 1995 135 141
2. D. Lloyd-Jones, R.J. Adams, and T.M. Brown Heart disease and stroke statistics - 2010 update A report from the American Heart Association Circulation 121 2010 e46 e215
3. V.L. Roger Epidemiology of heart failure Circ Res 113 2013 646 659
4. A.L. Bui, T.B. Horwich, and G.C. Fonarow Epidemiology and risk profile of heart failure Nat Rev Cardiol 8 2010 30 41
5. R.M. Saraiva, and J.M. Hare Nitric oxide signaling in the cardiovascular system: implications for heart failure Curr Opin Cardiol 21 2006 221 228
6. M. Guazzi Clinical use of phosphodiesterase-5 inhibitors in chronic heart failure Circ Heart Fail 1 2008 272 280
7. P. de Groote, A. Millaire, and C. Foucher-Hossein Right ventricular ejection fraction is an independent predictor of survival in patients with moderate heart failure J Am Coll Cardiol 32 1998 948 954
8. J. Butler, D.B. Chomsky, and J.R. Wilson Pulmonary hypertension and exercise intolerance in patients with heart failure J Am Coll Cardiol 34 1999 1802 1806
9. T.G. Di Salvo, M. Mathier, and M.J. Semigran Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure J Am Coll Cardiol 25 1995 1143 1153
10. S. Ghio, A. Gavazzi, and C. Campana Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure J Am Coll Cardiol 37 2001 183 188
11. G.D. Lewis, J. Lachmann, and J. Camuso Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure Circulation 115 2007 59 66
12. A.H. Cohen, K. Hanson, and K. Morris Inhibition of cyclic 3'-5'-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats J Clin Investig 97 1996 172 179
13. E. Salem, M. Kendirci, and W. Hellstrom Udenafil, a long-acting PDE5 inhibitor for erectile dysfunction Current opinion in investigational drugs (London, England: 2000) 7 2006 661
14. D. Kouvelas, A. Goulas, and G. Papazisis PDE5 inhibitors: in vitro and in vivo pharmacological profile Curr Pharm Des 15 2009 3464 3475
15. J.S. Paick, S.W. Kim, and D.Y. Yang The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction J Sex Med 5 2008 946 953
16. K. Kang, G. Ahn, and Y. Sohn DA-8159, a new PDE5 inhibitor, attenuates the development of compensatory right ventricular hypertrophy in a rat model of pulmonary hypertension J Int Med Res 31 2003 517 528
17. W.H. Frishman Importance of medication adherence in cardiovascular disease and the value of once-daily treatment regimens Cardiol Rev 15 2007 257 263
18. A.A. Fitzgerald, J.D. Powers, and P.M. Ho Impact of medication nonadherence on hospitalizations and mortality in heart failure J Card Fail 17 2011 664 669
19. A.H. Paes, A. Bakker, and C.J. Soe-Agnie Impact of dosage frequency on patient compliance Diabetes Care 20 1997 1512 1517
20. K.-H. Kim, H.-K. Kim, and I.-C. Hwang ULTIMATE-SHF trial (UdenafiL Therapy to Improve symptoMAtology, exercise Tolerance and hEmodynamics in patients with chronic systolic heart failure): study protocol for a randomized, placebo-controlled, double-blind trial Trials 14 2013 188
21. W.L. Beaver, K. Wasserman, and B.J. Whipp A new method for detecting anaerobic threshold by gas exchange J Appl Physiol 60 1986 2020 2027
22. R.P. Kelly, C.-T. Ting, and T.-M. Yang Effective arterial elastance as index of arterial vascular load in humans Circulation 86 1992 513 521
23. D. Chemla, J.-L. Hébert, and C. Coirault Total arterial compliance estimated by stroke volume-to-aortic pulse pressure ratio in humans Am J Physiol Heart Circ Physiol 274 1998 H500 H505
24. P.C. O'Brien, and T.R. Fleming A multiple testing procedure for clinical trials Biometrics 1979 549 556
25. P. Pokreisz, S. Vandenwijngaert, and V. Bito Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice Circulation 119 2009 408 416
26. E. Takimoto, H.C. Champion, and M. Li Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy Nat Med 11 2005 214 222
27. K.-H. Kim, Y.-J. Kim, and J.-H. Ohn Long-Term Effects of Sildenafil in a Rat Model of Chronic Mitral Regurgitation Benefits of Ventricular Remodeling and Exercise Capacity Circulation 125 2012 1390 1401
28. M. Guazzi, M. Vicenzi, and R. Arena PDE5 Inhibition With Sildenafil Improves Left Ventricular Diastolic Function, Cardiac Geometry, and Clinical Status in Patients With Stable Systolic Heart Failure Results of a 1-Year, Prospective, Randomized, Placebo-Controlled Study Circ Heart Fail 4 2011 8 17
29. G.D. Lewis, R. Shah, and K. Shahzad Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension Circulation 116 2007 1555 1562
30. M. Guazzi, G. Tumminello, and F. Di Marco The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure J Am Coll Cardiol 44 2004 2339 2348
31. W.L. Miller, D.W. Mahoney, and H.I. Michelena Contribution of ventricular diastolic dysfunction to pulmonary hypertension complicating chronic systolic heart failure J Am Coll Cardiol Img 4 2011 946 954
32. P. Kardas The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes) Diabetes Obes Metab 7 2005 722 728
33. W. Mullens, A.G. Borowski, and R.J. Curtin Tissue Doppler imaging in the estimation of intracardiac filling pressure in decompensated patients with advanced systolic heart failure Circulation 119 2009 62 70
34. G.J. Balady, R. Arena, and K. Sietsema American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee of the Council on Clinical Cardiology; Council on Epidemiology and Prevention; Council on Peripheral Vascular Disease; Interdisciplinary Council on Quality of Care and Outcomes Research. Clinician's Guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association Circulation 122 2010 191 225
35. J. Magne, P. Lancellotti, and L.A. Piérard Exercise pulmonary hypertension in asymptomatic degenerative mitral regurgitation Circulation 122 2010 33 41